secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001213900-24-022736
Event type: regulatory
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA delays response to 60 Degrees Pharma's babesiosis trial protocol to April 2024
--------------------------------------------------------------------------------

- FDA communicated intention to respond to babesiosis trial protocol in April 2024, not March 2024 as anticipated.
- Company maintains preparations for June 1, 2024 start date as previously communicated.
- Protocol submission is under existing IND; FDA has no specified response timeframe.
- Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis since 2018.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024022736/0001213900-24-022736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024022736/ea0201831-8k_60degree.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer